Breast Biopsy for Breast Cancer: Types, Procedure, Pain, Risks, Results and Cost in India

A breast biopsy collects a small sample of breast tissue or cells for microscopic examination. It is often recommended when examination or imaging identifies a suspicious lump or abnormality. This guide explains biopsy types, procedure, pain, pathology reports, biomarkers and what patients should know about getting a breast biopsy in India. Related care: diagnosis tests, screening, treatment in India and cost.

Being told you need a breast biopsy can be frightening, but it does not mean cancer has been confirmed. Doctors remove a small sample so a pathologist can determine whether the abnormality is cancerous, non-cancerous or needs further investigation.

Imaging can identify an abnormality but cannot always establish what it is. For suspected breast cancer in India, core needle biopsy is generally preferred because tissue can be examined for tumour type, grade and biomarkers. See breast cancer diagnosis.

A breast biopsy removes cells or tissue for laboratory examination. The report helps determine whether findings are benign or malignant, the cancer type if present, invasive versus non-invasive disease, tumour grade and whether hormone-receptor and HER2 testing are required.

No. Many lumps are benign (for example fibroadenomas, simple cysts, fibrocystic changes or fat necrosis). Some can be assessed with examination and imaging alone. Others need biopsy when appearance is suspicious or findings are inconclusive. Decisions follow combined clinical, imaging and pathology assessment.

Recommendations often follow triple assessment — clinical examination, imaging and pathology considered together:

Important: BI-RADS 4 or 5 does not confirm cancer — it indicates further investigation, generally including tissue sampling. More on screening and BI-RADS.

FNAC uses a very thin needle to collect cells or fluid. It is usually quick with minimal discomfort and no stitches. It can assess selected lumps, drain cysts or sample selected lymph nodes. Limitations: it collects cells rather than intact tissue architecture and may not support full biomarker assessment. Core needle biopsy is generally preferred when definitive tissue diagnosis and biomarkers are needed.

A hollow needle removes small cylindrical tissue cores, usually under local anaesthesia and often with ultrasound guidance. Tissue structure is preserved so pathologists can assess histological type, grade, invasive versus in-situ disease, ER, PR, HER2 and Ki-67 when appropriate — findings that guide treatment.

A specialised vacuum-assisted needle collects multiple samples through a small skin opening. It may be used for small abnormalities, suspicious microcalcifications or lesions needing more extensive sampling, and can reduce the need for surgical biopsy in selected cases.

Incisional biopsy removes part of an abnormality; excisional biopsy removes the whole area, sometimes with a margin. Surgical biopsy may follow inconclusive needle sampling, radiology–pathology discordance or lesions that cannot be adequately sampled with a needle. Needle biopsy is preferred when it can provide a reliable diagnosis before treatment planning.

There is no single best method for every patient. For suspected breast cancer, core needle biopsy is generally preferred when feasible. Choose the technique that answers the clinical question — not simply the newest or most expensive option. Discuss with surgical oncology specialists or your breast team.

Most image-guided needle biopsies use local anaesthesia. You may feel a brief sting from the anaesthetic, pressure when the needle is positioned, clicking from the device, and mild soreness, bruising or swelling afterwards. Sharp pain during sampling should be uncommon once the area is numb — tell the doctor if pain is significant.

Mild tenderness, swelling or bruising is usually temporary. Doctors may advise a cold pack, a supportive bra, avoiding strenuous activity for about 24 hours and keeping the site clean. Contact the team for uncontrolled bleeding, rapidly increasing swelling, severe pain, fever, spreading redness or unusual discharge.

A straightforward report may be ready within a few working days. Extra sections, immunohistochemistry, HER2 confirmation or second-pathologist review can take longer. Ask when and how results will be shared.

Cancer was not identified in the sampled tissue (for example fibroadenoma, fibrocystic change, cyst-related change or fat necrosis). Results must still match imaging. Radiology–pathology discordance may lead to repeat or surgical biopsy.

Findings such as ADH, ALH, LCIS, selected papillary lesions or radial scar are not invasive cancer but may need excision or surveillance based on sampling, imaging and risk factors.

Cancer cells are present (for example invasive ductal or lobular carcinoma, or DCIS). Further biomarker testing guides biology and treatment. See stages.

When cancer is confirmed, biomarkers help choose therapy:

Equivocal HER2 IHC (often 2+) may need ISH confirmation. These tests support classification into hormone receptor-positive, HER2-positive and triple-negative groups but do not replace the full pathology report. Details: ER/PR/HER2 diagnosis guide.

An excisional biopsy can remove a small abnormality but is not necessarily definitive cancer surgery. Confirmed cancer may still need further surgery or systemic therapy. See breast cancer surgery in India.

A benign or inconclusive report should not end investigation if clinical and imaging findings remain suspicious.

Cost varies by method, hospital, city, imaging guidance and pathology tests. FNAC differs from image-guided core, vacuum-assisted or surgical biopsy. Factors include:

There is no single nationwide price. Ask for an itemised estimate covering the procedure, guidance, anaesthesia/consumables, histopathology, ER/PR/HER2 (± ISH) and follow-up. Do not compare quotations unless inclusions match.

Related GAF cost reading: breast cancer treatment cost in India. Specialists: medical oncology, Delhi NCR, Mumbai.

Patients from Tanzania, Kenya, Uganda, Ethiopia, Zambia, Iraq, Oman and other countries should share prior mammograms, ultrasound/MRI reports (DICOM when possible), pathology slides or blocks if already biopsied, medicines list and family history before travel. A typical pathway: specialist consultation → review of records → additional imaging if needed → image-guided biopsy → pathology ± biomarkers → multidisciplinary discussion. GAF Healthcare can coordinate appointments; clinical decisions remain with the treating team. See international patients guide.

Confirmation starts treatment planning: review type and grade, biomarkers, breast and axillary imaging, staging needs and multidisciplinary options. Treatment may include breast-conserving surgery or mastectomy, sentinel node assessment, chemotherapy, radiation, hormone therapy, HER2-targeted therapy or immunotherapy in selected cases. Neoadjuvant therapy before surgery makes an adequate pre-treatment core biopsy and biomarkers especially important. Continue with follow-up testing after treatment.

No. A biopsy determines whether an abnormality is cancerous. Many breast biopsies show benign conditions.

Most needle biopsies use local anaesthesia. You may feel a brief sting from the injection and pressure during sampling. Mild soreness or bruising can occur afterwards.

Core needle biopsy is generally preferred because it provides tissue for histology and biomarker testing. The method still depends on the abnormality and imaging findings.

FNAC can identify suspicious or malignant cells in selected cases, but it does not preserve tissue architecture and may not support full biomarker planning. Core needle biopsy is generally preferred when feasible.

Many needle biopsies are completed within about an hour including preparation. Duration varies with technique and imaging guidance.

Most patients having a needle biopsy return home the same day. Surgical biopsy may involve a different recovery plan.

Timing varies by laboratory and tests required. A straightforward report may arrive within a few working days; immunohistochemistry or HER2 confirmation can take longer.

Benign means cancer was not identified in the sampled tissue. Malignant means cancer cells were found. Both must be interpreted with imaging and clinical findings.

There is no good evidence that a properly performed breast needle biopsy causes clinically meaningful spread. Accurate tissue diagnosis remains important.

A very small device placed at the biopsy site in selected cases so doctors can locate the area later during imaging, surgery or treatment.

The team checks radiology–pathology concordance. If findings do not match, repeat biopsy or surgical biopsy may be recommended.

For newly diagnosed invasive breast cancer these biomarkers are important for treatment planning. Exact tests depend on the pathology and clinical situation.

A clinically necessary biopsy can be performed in pregnancy. The clinician chooses an appropriate procedure and imaging approach for the patient.

Most needle biopsies use local anaesthesia. Surgical biopsies may use local anaesthesia with sedation or general anaesthesia depending on the procedure.

Some vacuum-assisted or surgical biopsies can remove a substantial part or all of a selected abnormality, but a diagnostic biopsy is not automatically definitive cancer surgery.

An abnormal lump or mammogram does not automatically mean cancer. A breast biopsy moves care from suspicion to accurate diagnosis. Core needle biopsy is generally preferred for suspected breast cancer because it supports type, grade and biomarker assessment. Choose the method that fits the imaging target, and ask why that method — and which laboratory tests — are planned.

An accurate diagnosis is the foundation of an appropriate breast cancer treatment plan. Next steps: breast cancer treatment in India · symptoms · screening.

Medical disclaimer: This article is for general educational purposes. It does not replace examination, imaging review, pathology interpretation or advice from a qualified healthcare professional.